Replies to post #252898 on Biotech Values

[dewophile]

This setback ought to be bullish for the flu/COVID combo vaccine programs from MRNA (#msg-174351482) and from SNY/NVAX (#msg-174392861).

agree yet MRNA is flat today. Perhaps the market is skeptical of the platform now. GSK also has a program by the way that is not too far behind

[DewDiligence]

BNTX +11% on info that I presume is related to ESMO.

The 11% gain in the BNTX’s share price and market cap equates to a roughly 40%(!) increase in BNTX’s enterprise value because the BNTX has a whopping $17B in net cash.